An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The study evaluated patients with stage III/IV melanoma after complete tumor resection
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
Highlighting KEYTRUDA & expanding cancer pipeline
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
